AMRI Announces Executive Leadership Changes
AMRI reported that Thomas E. D'Ambra, PhD. will retire as president and CEO.
Albany Molecular Research (AMRI), a provider of contract discovery, development and manufacturing services, has announced that Thomas E. D’Ambra, PhD, will retire as president and CEO, effective Dec. 31, 2013. D’Ambra will be named the company’s nonexecutive chairman of the board of directors on the same date.
D’Ambra will be succeeded as president and CEO by William S. Marth, currently nonexecutive chairman of the AMRI Board, effective Jan. 1, 2014. Marth will remain a member of the company’s board of directors.
Source: Albany Molecular Research
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
